AGM voting

Novacyt S.A.

14 September 2023

 

 

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

AGM voting

Paris, France, and Eastleigh UK - 14 September 2023 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that shareholders are now able to vote for the Company's rescheduled Annual General Meeting ("AGM"), which will be held at 1pm BST/2pm CEST on 5 October 2023 as an open virtual meeting.

The Company's Annual General Meeting ("AGM") will be held exclusively as an open online meeting at 1pm BST/2pm CEST on Thursday, 5 October 2023. As this is a rescheduled meeting, all previous votes are now void and all shareholders must resubmit their votes.

As usual, and in accordance with French corporate law, the AGM comprises both ordinary and extraordinary resolutions. All materials can be found at www.novacyt.com/investors.

Shareholders are strongly encouraged to submit their votes in advance, in accordance with the instructions in the Notice of the AGM.

Under French law, for the AGM and EGM meetings to be quorate at the first attempt, shareholders representing at least 20% of the share capital and voting rights, on ordinary resolutions, and 25% of the share capital and voting rights, on extraordinary resolutions, must be present, represented or have voted in advance under the conditions set out below.

Shareholders can vote in advance of the AGM by:

·   Downloading a copy of the proxy voting form from the website www.novacyt.com/investors, completing it and returning it together with evidence of their shareholding which must be in the form of a share certificate (attestation), either by post to the following address: 6 avenue de Provence 75452 Paris Cedex 09, or via email to the following address: [e-mail], or [e-mail],  no later than 2 October 2023 inclusive.

·   Voting on-line using the Votaccess portal http://www.actionnaire.cic-marketsolutions.eu  if securities held on Euronext Growth are registered with any of the following banks: CIC, Natixis, Société Générale, Caceis, Crédit Agricole, BP2S, BNP Retail, Bourse Direct, ODDO, Rothschild Martin Maurel, Procapital, Citibank, Deutsche Bank, Bank of New York or JP Morgan. The Votaccess portal will be open from 15 September 2023 to 4 October 2023 2pm BST/3pm CEST.

·   Voting on-line via a broker, nominee, bank or authorised intermediary. Many intermediaries in the UK such as Hargreaves Lansdown are now using the Broadridge ProxyVote on-line voting portal.

Shareholders can register for the AGM and access the online meeting by visiting https://novacytagm23.eventcaster.co.uk. Registration must be accompanied by formal evidence of shareholding. As this is a rescheduled meeting, all previous registrations are now void and all shareholders must re-register.

Following registration approval, shareholders will be able to virtually attend the AGM and vote online during the meeting if they wish, providing formal evidence of holding has been provided prior to the meeting.

Shareholders who have voted (through a proxy, via their broker, nominee, bank, authorised intermediary, Votaccess portal or Broadridge ProxyVote) will be allowed to attend the AGM online but will not be able to vote twice.

Following the meeting, a recording of the AGM will be available on the Company's website at www.novacyt.com/investors.

Contacts

Novacyt SA		[phone]
James Wakefield, Non-Executive Chairman James McCarthy, Acting Chief Executive Officer
SP Angel Corporate Finance LLP (Nominated Adviser and Broker)			[phone]
Matthew Johnson / Charlie Bouverat (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking)
Numis (Joint Broker)			[phone]
Freddie Barnfield / Duncan Monteith / Jack McLaren
Allegra Finance (French Listing Sponsor) Rémi Durgetto / Yannick Petit			[phone] [e-mail] / [e-mail]
Walbrook PR (Financial PR & IR) Stephanie Cuthbert / Anna Dunphy / Phillip Marriage		[phone] [e-mail]

About Novacyt Group

Novacyt is an international diagnostics business delivering a broad portfolio of in vitro and molecular diagnostic tests for a wide range of infectious diseases, enabling faster, more accurate, accessible testing to improve healthcare outcomes. The Company provides customers with a seamless sample-to-result workflow using its integrated and scalable instrumentation/solutions. The Company specialises in the design, manufacture, and supply of real-time PCR kits, reagents and a full range of laboratory and qPCR instrumentation for molecular biology research and clinical use. Novacyt offers one of the world's most varied and comprehensive range of qPCR assays, covering human, veterinary, biodefence, environmental, agriculture and food testing.

The acquisition of Yourgene in September 2023 added a complementary international genomics technology and services business, focussed on delivering accurate molecular diagnostic and screening solutions, across reproductive health and precision medicine. Yourgene's portfolio of in vitro diagnostic products includes non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests and DPYD genotyping assays. Yourgene also works in partnership with global leaders in DNA technology to allow its Ranger® Technology to deliver dynamic target enrichment.

Novacyt is headquartered in Vélizy in France with offices in the UK in Stokesley, Eastleigh and Manchester. The Company also has offices in Taipei (divestment pending), Singapore, the US and Canada and is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

For more information, please refer to the website: www.novacyt.com

 

END